489 6. Complicanze tardive of resistant chronic graft versus host disease. Br J Haematol. 2005;130(3):409–417. [71] Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid refractory chronic graft versus host disease. Blood. 2006;108(2):756– 762. [72] Kharfan Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Efficacy of rituximab in the setting of steroid refractory chronic graft versus host disease: a systematic review and meta analysis. Biol Blood Marrow Transplant. 2009;15(9):1005–1013. [73] Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549. [74] Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft versus host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250. [75] Pai CC, Chen M, Mirsoian A, et al. Treatment of chronic graft versushost disease with bortezomib. Blood. 2014;124(10):1677– 1688. [76] Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroidrefractory graft versus host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068. [77] Whangbo JS, Antin JH, Koreth J. The role of regulatory T cells in graftversus-host disease management. Expert Rev Hematol. 2020;13(2): 141–154. [78] Betts BC, Veerapathran A, Pidala J, et al. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Sci Transl Med. 2017;9(372):eaai8269. [79] Fransolet G, Ehx G, Somja J, et al. Azacytidine mitigates experimental sclerodermic chronic graft versus host disease. J Hematol Oncol. 2016;9(1):53. [80] Mohammadi S, Malek Mohammadi A, Norooznezhad AH, et al. Extra corporeal photochemotherapy in steroid refractory graft versus host disease: A review of guidelines and recommendations. Transfus Apher Sci. 2017;56(3):376–384. [81] Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft versus host disease. Blood. 2002;100(3):941–947. [82] Fimiani M, Di Renzo M, Rubegni P. Mechanism of action of extracorporeal photochemotherapy in chronic graft versus host disease. Br J Dermatol. 2004;150(6):1055–1060. [83] Denney HA, Whittle RJ, Lai J, et al. Regulatory T Cells in chronic graft versus host disease after extracorporeal photopheresis: correlation with skin and global organ responses, and ability to taper steroids. Transplantation. 2017;101(1):204–211. [84] Malik MI, Litzow M, Hogan W, et al. Extracorporeal photopheresis for chronic graft versus host disease: a systematic review and meta analysis. Blood Res. 2014;49:100–106. [85] Abu Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid refractory acute or chronic graft versus host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20(11):1677–1686. [86] Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft versus Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21(7):1167–1187. [87] Mello M, Tanaka C, Dulley FL. Effects of an exercise program on muscle performance in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;32:723– 728. [88] Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft versus host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft versus Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–396 [89] Elad S, Or R, Resnick I, et al. Topical tacrolimus: a novel treatment alternative for cutaneous chronic graft versus host disease. Transplnt. 2003;16:665–670. [90] Schmook T, Kraft J, Benninghoff B, et al. Treatment of cutaneous chronic graft versus host disease with topical pimecrolimus. Bone Marrow Transplant. 2005;36:87–88 [91] Castellsague J, Kuiper JG, Pottegård A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus,and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation: JOELLE study). Clin Epidemiol. 2018;10:299–310. [92] Leiter U, Kaskel P, Krahn G, et al. Psoralen plus ultraviolet A bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed. 2002;18:183–190. [93] Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graftversus host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061–1067. [94] Jampel RM, Farmer ER, Vogelsang GB, et al. PUVA therapy for chronic cutaneous graft vs host disease. Arch Dermatol. 1991;127:1673–1678. [95] Ghoreschi K, Thomas P, Penovici M, et al. PUVA bath photochemotherapy and isotretinoin in sclerodermatous graft versus host disease. Eur J Dermatol. 2008;18:667–670. [96] Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drugresistant graft versus host disease. Bone Marrow Transplant.1986;1:227–236. [97] Grundmann Kollmann M, Behrens S, Gruss C, et al. Chronic sclerodermic graft versus host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol. 2000;42(1 Pt 1):134–136. [98] Wetzig T, Sticherling M, Simon JC, et al. Medium dose long wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft versus host disease of the skin. Bone Marrow Transplant. 2005;35:515–519. [99] Calzavara PP, Porta F, Izzi T, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft versus host disease. Haematologica. 2003;88:1169–1175. [100] Enk CD, Elad S, Vexler A, et al. Chronic graft versus host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22: 1179–1183. [101] Kolb HJ, Socié G, Duell T, et al. Malignant neoplasms in long term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. 1999;131:738–744. [102] Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904. [103] Rostagno E, Campanati A, Mordini N, Cannici C, Cioce M, De Cecco V, Samarani E, Foà R, Olivieri A, Botti S. Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):1003-1015. doi: 10.1111/jdv.18
RkJQdWJsaXNoZXIy ODUzNzk5